consultant medical oncologist at Mount Vernon Cancer Centre in Middlesex, UK. He added, however, that there "remains much work to be done to build upon this advance," so that they can "further ...

Doorbell cameras are increasingly playing a role in crime prevention and investigations, so Mount Vernon officials hope free surveillance cameras for residents will help the city's public safety ...

Mt. Vernon's season ended with a 63-59 loss to Jeffersonville in Saturday's Class 4A semistate semifinal at New Castle. The Marauders knocked off No. 5 Anderson and No. 2 Greenfield-Central to win ...

2026 Purdue basketball commit Luke Ertel scored 19 points, leading Mt. Vernon to a 76-40 win over Brownsburg in the Class 4A Regional on Saturday. Mt. Vernon has advanced to the semi-state round ...

by KOMO News Staff TOPICS: MOUNT VERNON, Wash. — An 18-year-old man is dead after a shooting at a Mount Vernon Chevron station late Monday night. Officers said they were dispatched to a report ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

MOUNT VERNON, Wash. — World-famous fields of tulips and daffodils have blossomed vibrantly across Skagit Valley, marking the return of the beloved (and photo-worthy) Skagit Valley Tulip Festival.

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a cash and debt-free basis, it said on Monday. The deal includes an initial ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...